EA202091732A1 - Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения - Google Patents
Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их примененияInfo
- Publication number
- EA202091732A1 EA202091732A1 EA202091732A EA202091732A EA202091732A1 EA 202091732 A1 EA202091732 A1 EA 202091732A1 EA 202091732 A EA202091732 A EA 202091732A EA 202091732 A EA202091732 A EA 202091732A EA 202091732 A1 EA202091732 A1 EA 202091732A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- mcv
- antigens
- nucleic acid
- poliomavirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619161P | 2018-01-19 | 2018-01-19 | |
| PCT/US2019/014171 WO2019143921A2 (en) | 2018-01-19 | 2019-01-18 | Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091732A1 true EA202091732A1 (ru) | 2020-09-10 |
Family
ID=67302504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091732A EA202091732A1 (ru) | 2018-01-19 | 2019-01-18 | Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11524065B2 (enExample) |
| EP (1) | EP3740226A4 (enExample) |
| JP (2) | JP7485604B2 (enExample) |
| KR (1) | KR20200110678A (enExample) |
| CN (2) | CN120514835A (enExample) |
| AU (2) | AU2019210063B2 (enExample) |
| BR (1) | BR112020014632A2 (enExample) |
| CA (1) | CA3088374A1 (enExample) |
| EA (1) | EA202091732A1 (enExample) |
| MX (1) | MX2020007676A (enExample) |
| WO (1) | WO2019143921A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019210063B2 (en) * | 2018-01-19 | 2025-03-06 | The Wistar Institute Of Anatomy And Biology | Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| WO2021247534A2 (en) * | 2020-06-01 | 2021-12-09 | The Broad Institute, Inc. | Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028165A2 (en) * | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| WO2016073595A1 (en) * | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| EP3101134A1 (en) * | 2015-06-05 | 2016-12-07 | Apcure SAS | Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors |
| WO2017060283A1 (en) * | 2015-10-06 | 2017-04-13 | Universität Basel | Specific immunodominant peptide epitopes for polyomavirus vaccine |
| AU2019210063B2 (en) * | 2018-01-19 | 2025-03-06 | The Wistar Institute Of Anatomy And Biology | Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same |
-
2019
- 2019-01-18 AU AU2019210063A patent/AU2019210063B2/en active Active
- 2019-01-18 WO PCT/US2019/014171 patent/WO2019143921A2/en not_active Ceased
- 2019-01-18 US US16/962,886 patent/US11524065B2/en active Active
- 2019-01-18 EA EA202091732A patent/EA202091732A1/ru unknown
- 2019-01-18 EP EP19741300.8A patent/EP3740226A4/en not_active Withdrawn
- 2019-01-18 MX MX2020007676A patent/MX2020007676A/es unknown
- 2019-01-18 CN CN202510692710.3A patent/CN120514835A/zh active Pending
- 2019-01-18 CA CA3088374A patent/CA3088374A1/en active Pending
- 2019-01-18 CN CN201980014819.4A patent/CN111801111B/zh active Active
- 2019-01-18 BR BR112020014632-3A patent/BR112020014632A2/pt unknown
- 2019-01-18 JP JP2020539735A patent/JP7485604B2/ja active Active
- 2019-01-18 KR KR1020207023370A patent/KR20200110678A/ko not_active Ceased
-
2022
- 2022-12-12 US US18/064,482 patent/US20230201328A1/en active Pending
-
2024
- 2024-05-02 JP JP2024074955A patent/JP2024096334A/ja active Pending
-
2025
- 2025-06-06 AU AU2025204247A patent/AU2025204247A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200345830A1 (en) | 2020-11-05 |
| AU2025204247A1 (en) | 2025-06-26 |
| WO2019143921A3 (en) | 2020-04-09 |
| US20230201328A1 (en) | 2023-06-29 |
| CN111801111B (zh) | 2025-06-10 |
| CN120514835A (zh) | 2025-08-22 |
| KR20200110678A (ko) | 2020-09-24 |
| BR112020014632A2 (pt) | 2021-01-05 |
| CA3088374A1 (en) | 2019-07-25 |
| MX2020007676A (es) | 2020-11-12 |
| CN111801111A (zh) | 2020-10-20 |
| AU2019210063B2 (en) | 2025-03-06 |
| JP2024096334A (ja) | 2024-07-12 |
| EP3740226A2 (en) | 2020-11-25 |
| WO2019143921A2 (en) | 2019-07-25 |
| JP2021511320A (ja) | 2021-05-06 |
| JP7485604B2 (ja) | 2024-05-16 |
| US11524065B2 (en) | 2022-12-13 |
| EP3740226A4 (en) | 2021-10-13 |
| AU2019210063A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092808A1 (ru) | Вакцины на основе наночастиц с новыми структурными компонентами | |
| EA201792080A1 (ru) | Гуманизированные анти-c1s антитела и способы их применения | |
| EA202091673A1 (ru) | Способ амплификации нуклеиновых кислот | |
| EA201990861A1 (ru) | Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения | |
| EA201791148A1 (ru) | Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| SG10201901053TA (en) | Novel tilapia virus and uses thereof | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| EA202090628A1 (ru) | Система экспрессии paramyxoviridae | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| WO2020065349A8 (en) | Vaccines and methods | |
| EA202192923A1 (ru) | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а | |
| BR112018007121A2 (pt) | anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv | |
| EP4353256A3 (en) | Induction of cross-reactive cellular response against rhinovirus antigens | |
| EA201990711A1 (ru) | Новый ehv сайт инсерции orf70 | |
| CL2021002226A1 (es) | Transactivadores de dominios de unión a adn y usos de estos | |
| EA202091732A1 (ru) | Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения | |
| EA201691981A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение | |
| ZA202404295B (en) | Anti-mutant calreticulin (calr) antibodies and uses thereof | |
| WO2018035199A8 (en) | Sea lice vaccine | |
| MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
| MX373809B (es) | Virus de la viruela porcina recombinante y vacunas. | |
| BR112016030008A2 (pt) | método para a detecção de infecção por pegivirus humano 2 em um indivíduo, para a detecção de ácido nucleico de pegivirus humano 2 e para a detecção de pegivirus humano 2 em uma amostra, e, composição | |
| GB2607723B (en) | Vector for cancer treatment | |
| Pugh et al. | Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000 |